Arguably the most notable of the FDA’s upcoming decisions is that regarding Gilead’s twice-yearly HIV prophylaxis lenacapavir ...

These real-world results support the effectiveness of maternal RSV vaccination and could influence policy decisions in other ...

Patients with RSV hospitalization have increased odds of any acute cardiovascular event compared with COVID-19 hospitalizations.

This Abrysvo or Arexvy market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the ...